https://www.selleckchem.com/products/bi-3812.html
19 [0.12-0.30] and 0.15 [0.06-0.39]; other methods were consistent). Vaccine protection was observed over the different study periods, being highest during the first 2 years. Evidence for a decreased risk of hospitalized and severe VCD was also observed in seropositive participants aged 6-8 years. Clinical signs and symptoms, and quantified dengue viremia from participants with hospitalized VCD were comparable between groups. CYD-TDV demonstrated robust protection against hospitalized and severe VCD over the entire six-year follow-up in
Like
Comment
Share
